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Abstract: G6PD deficiency renders cells more susceptible to oxidative insults, while antioxidant
dietary supplementation could restore redox balance and ameliorate exercise-induced oxidative stress.
To examine the effects of alpha-lipoic acid (ALA) supplementation on redox status indices in G6PD
deficient individuals, eight male adults with G6PD deficiency (D) participated in this randomized
double-blind placebo-controlled crossover trial. Participants were randomly assigned to receive
ALA (600 mg/day) or placebo for 4 weeks separated by a 4-week washout period. Before and at
the end of each treatment period, participants exercised following an exhaustive treadmill exercise
protocol. Blood samples were obtained before (at rest), immediately after and 1h after exercise for
later analysis of total antioxidant capacity (TAC), uric acid, bilirubin, thiobarbituric acid reactive
substances (TBARS) and protein carbonyls (PC). ALA resulted in significantly increased resting TAC
and bilirubin concentrations. Moreover, TAC increased immediately and 1h after exercise following
both treatment periods, whereas bilirubin increased immediately after and 1h after exercise following
only ALA. No significant change in uric acid, TBARS or PC was observed at any time point. ALA
supplementation for 4 weeks may enhance antioxidant status in G6PD individuals; however, it does
not affect redox responses to acute exercise until exhaustion or exercise performance.
Keywords: antioxidant; enzymopathy; oxidative stress; exercise performance; muscle
1. Introduction
Glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency is the most common
enzymopathy, affecting more than 400 million people worldwide [1]. G6PD is involved in the
generation of NADPH, a reducing agent that participates in various anabolic pathways and the
regeneration of reduced glutathione (GSH) [2]. G6PD deficient cells have lower concentrations of
GSH. Since GSH protects cells against reactive oxygen species (ROS), G6PD deficiency renders cells
susceptible to oxidative stress and its consequences.
Deficient G6PD activity is well examined in red blood cells (RBC), as it often results in clinical
manifestation of mild to severe haemolytic anaemia following exposure to various oxidative agents
such as certain drugs [1]. Although G6PD deficient activity is also present in other cells such as
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white blood cells and myocytes, theoretically causing different clinical symptoms under conditions of
increased oxidative stress, research in this field is limited.
Intense exercise results in an increased use of oxygen by the working muscles and generation of
ROS [3]. The antioxidant defence systems minimize the damage caused by ROS; however, when these
systems cannot efficiently remove the ROS, an imbalance in favour of ROS production occurs which
is known as oxidative stress. Since G6PD deficient individuals have lower endogenous antioxidant
system, intense exercise could result in increased oxidative stress in RBC and myocytes, which in turn
could cause haemolytic anaemia and/or muscular symptoms, respectively.
For this reason, it has been postulated that G6PD-deficient individuals should avoid performing
heavy physical exercise [4]. Indeed, symptoms such as haemolysis, muscle degeneration, myalgia
and myoglobinuria have been reported following intense exercise [5–8]. Nevertheless, experimental
studies have not detected greater levels of exercise-induced oxidative stress or signs of haemolysis in
G6PD deficient individuals compared to individuals with normal G6PD activity [9–11]. On the other
hand, it is well known that physical activity/exercise contributes to the maintenance and promotion of
health. To date there are no guidelines for exercise in G6PD deficient individuals.
Enhancement of antioxidant defence mechanisms in G6PD-deficient individuals could result
in safer participation in exercise. Theoretically, restoration of GSH concentrations would enhance
these mechanisms, rending cells less susceptible to oxidative insults. Since GSH formation greatly
depends on cysteine, dietary supplements with antioxidants or cysteine donors such as α-lipoic acid
(ALA) could positively influence recovery following exercise in G6PD deficient individuals. Trace
amounts of LA are synthesized by the human body, while exogenously supplied ALA is reduced to
dihydrolipoate (DHLA) by NADH- or NADPH-dependent enzymes in several tissues [12–14]. DHLA
provides cysteine by reducing cystine, which is abundant in the extracellular compartment [15] and
it is then oxidized to ALA. ALA has the ability to continuously supply cysteine as long as it gets
reduced to DHLA by intracellular enzymes [15,16]. Cysteine is a precursor for glutathione synthesis,
and its intracellular availability plays a major role in cellular glutathione levels [16]. Since ALA has the
ability to continuously supply cysteine, it increases intracellular GSH. Indeed, studies have shown that
ALA supplementation increases intracellular GSH levels in various cell types and tissues [15,17,18]
in various pathological conditions [18] including G6PD deficiency [19]. Thus ALA supplementation
could be beneficial for individuals with G6PD deficiency who perform exercise. The purpose of this
study was to examine the effects of 4-week ALA supplementation on blood redox status in males with
G6PD deficiency following acute exercise.
2. Materials and Methods
2.1. Subjects
Eight healthy males (age: 38.4 ± 5.6 years) with G6PD deficiency participated in this study.
Participants were recreationally trained, as evidenced by their maximal oxygen consumption (VO2max)
level (mean VO2max: 40.7 ± 1.7 mL/kg/min) and were non-smokers. Participants abstained from any
vigorous physical activity and the consumption of caffeine and alcohol for at least two days before
each exercise trial.
Exclusion criteria included intake of performance-enhancing or antioxidant supplements and
medications over the last 6 months and during the study, a known ALA intolerance, and any medical
condition that contraindicates participation to exercise.
Participants were informed about the study procedures, risks and benefits involved in the
study and signed an informed consent form. Procedures were in accordance with the 1975
Declaration of Helsinki (2000). Approval was previously obtained from the Institutional Review
Board of the University of Thessaly (protocol number 1076). Moreover, this study was registered at
ClinicalTrials.gov as NCT02937363 [20].
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2.2. Experimental Design
The study was a randomized double-blind placebo-controlled crossover trial. Participants were
randomly assigned to receive ALA (600 mg/day) or placebo (PL) for 4 weeks separated by a 4-week
washout period. Before and at the end of each period, participants exercised on a treadmill (a total
of four exercise trials) at an intensity corresponding to 70–75% of their VO2max for 45 min and then
at 90% of their VO2max until exhaustion. Blood samples were obtained before (at rest), immediately
after and 1 h after exercise.
Participants recorded their diet for two days before their first exercise trial and they followed the
same diet before each of the subsequent exercise trial. Moreover, participants were instructed to avoid
any strenuous physical activity for at least two days before each exercise trial. Exercise trials were
performed in the morning after an overnight fast (10 h).
2.3. Physical Characteristics and Physical Activity Level
Body height was measured to the nearest 0.1 cm and body weight to the nearest 0.1 kg (Beam
Balance, Seca, UK), with the participants lightly dressed and barefoot. Body fat percentage was
estimated by dual-energy X-ray absorptiometry (DEXA) (Lunar DPX NT, GE Healthcare, UK).
The level of physical activity of the participants was determined by using the Greek version of
the International Physical Activity Questionnaire (IPAQ) [21].
2.4. Exercise Performance
Aerobic fitness (VO2max test): VO2max was determined using a treadmill test to exhaustion.
The test commenced at a speed corresponding to ~60% of each participant’s predicted VO2max
(Karvonen Formula: Target heart rate = ((220 − age in years) − resting heart rate) × (% intensity) +
resting heart rate) for the first two minutes. Then, speed increased by 0.5 km/h every minute until
exhaustion. Heart rate was monitored every minute (Polar RC3 GPS HR; Polar Electro Oy, Kempele,
Finland). VO2 uptake, and CO2 production were continuously recorded via a computerized online gas
analysis system (SensorMedics 2900c, SensorMedics Corporation, Yorba Linda, CA, USA) calibrated to
known gases.
Aerobic endurance (time to exhaustion test): Time to exhaustion was measured using an exhaustive
treadmill exercise protocol that has been previously described [9].
Muscle function and performance (isometric peak torque): An isokinetic dynamometer (Cybex,
HUMAC NORM 360, Ronkonkoma, NY, USA) was used for the evaluation of knee extensor
performance of both legs by measuring isometric peak torque at 90◦ knee flexion before each exercise
trial. The best of the three maximal voluntary contractions (MVC) (performed with one minute rest
between efforts) was recorded. If the difference between the lower and the higher torque values
exceeded 10% the measurements were repeated.
2.5. Blood Collection and Handling
To determine whether participants were G6PD deficient before their enrolment to the study, a
blood sample was obtained for the measurement of G6PD activity in red blood cells. A portion of
whole blood was collected and handled as previously described [19].
Blood samples during the study were obtained for later analysis of total antioxidant capacity
(TAC), uric acid, bilirubin, thiobarbituric acid reactive substances (TBARS) and protein carbonyls in
serum. Blood handling for serum preparation has been described elsewhere [19].
2.6. Blood Sample Analysis
All indices were analysed in duplicates. G6PD activity was measured on the day of blood sample
collection. Indices of blood redox status were measured after samples had undergone only one
freeze-thaw cycle.
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For TAC determination 20 µL of serum were added to 480 µL of 10 mM sodium potassium
phosphate (pH 7.4) and 500 µL of 0.1 mM 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical, the
samples were incubated in the dark for 30 min at room temperature and then they were centrifuged
for 3 min at 20,000× g. Their absorbance was read at 520 nm.
Uric acid and bilirubin in serum were determined using commercially available kits (Zafiropoulos
Diagnostica, Athens, Greece) in a Clinical Chemistry Analyzer Z 1145 (Zafiropoulos Diagnostica,
Athens, Greece). Several studies have shown that bilirubin has antioxidant activities [22] that contribute
towards the total antioxidant capacity whereas reports indicate that uric acid contributes significantly
towards the plasma total antioxidant activity [23]. Therefore, these two indices were additionally
included in the biochemical analyses to elucidate the role of ALA supplementation on exercise-induced
oxidative stress.
For TBARS determination 100 µL of serum was mixed with 500 µL of 35% TCA and 500 µL of
Tris–HCl (200 mM, pH 7.4). The samples were incubated for 10 min at room temperature, then 1 mL of
2 M Na2SO4 and 55 mM thiobarbituric acid solution were added, and the samples were incubated at
95 ◦C for 45 min. After 5 min on ice, 1 mL of 70% TCA was added and the samples were vortexed,
then centrifuged at 15,000× g for 3 min, and the absorbance of the supernatant was read at 530 nm. A
blank was also run along with samples during the measurement. Calculation of TBARS levels was
based on the molar extinction coefficient of malondialdehyde.
For the determination of protein carbonyls 50 µL of 20% TCA were added to 50 µL of serum.
The samples were incubated in an ice bath for 15 min and centrifuged at 15,000× g for 5 min at 4 ◦C.
The supernatant was discarded, and 500 µL of 10 mM 2,4-dinitrophenylhydrazine (in 2.5 N HCL) for
the samples or 500 µL of 2.5 N HCL for the blanks were added. All samples were incubated in the
dark at room temperature for 1 h, with intermittent vortexing every 15 min, and were then centrifuged
at 15,000× g for 5 min at 4 ◦C. The supernatant was discarded, 1 mL of 10% TCA was added, vortexed,
and centrifuged at 15,000× g for 5 min at 4 ◦C. The supernatant was discarded, 1 mL of ethanol-ethyl
acetate was added, vortexed, and centrifuged at 15,000× g for 5 min at 4 ◦C. This step was repeated
twice and then the supernatant was discarded, 1 mL of 5 M urea (pH 2.3) was added, vortexed, and
incubated at 37 ◦C for 15 min. They were centrifuged at 15,000× g for 3 min at 4 ◦C, and the absorbance
was read at 375 nm. Calculation of protein carbonyl concentration was based on the molar extinction
coefficient of dinitrophenylhydrazine.
2.7. Statistical Analysis
Power analysis performed with data from a previous [19] showed that the minimum required
sample size was 8 for a 2-sided type 1 error of 5%.
Data are expressed as mean ± SEM. Changes in dependent variables were examined with a
two-way repeated-measures ANOVA [condition (ALA and PL) × time (before exercise, immediately
after exercise, one hour after exercise)]. If a significant interaction was detected, pairwise comparisons
were performed through simple contrasts and simple main effects analysis using the Bonferroni
test method. Pre- and post-measurements within conditions were compared using paired t-tests.
Significance was set at p ≤ 0.05. The statistical programme used was SPSS version 18.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results
All participants completed both arms of the study, while no adverse effect was reported. Erythrocyte
G6PD activity was 0.502 ± 0.01 U/g Hb (with normal ranging from 4.5 to 13.5 U/g Hb).
Baseline physical characteristics of the participants were similar between ALA and PL (Table 1),
indicating that measurements were performed under the same conditions. Physical characteristics
did not change throughout the study, except for resting heart rate (HR), which decreased following
ALA (Table 1). Regarding exercise performance, treadmill time to exhaustion and MVC did not change
throughout the study (Table 2).
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Table 1. Physical characteristics of the participants following α-lipoic acid supplementation (ALA) and
placebo (PL).
Parameter ALA PL
Pre Post Pre Post
Body Weight (kg) 81.64 ± 5.65 81.67 ± 5.32 81.53 ± 5.96 82.00 ± 5.86
BMI (kg/m2) 25.99 ± 1.50 26.02 ± 1.40 25.94 ± 1.58 26.09 ± 1.53
% Body Fat 25.84 ± 2.16 25.36 ± 2.32 25.43 ± 2.18 26.37 ± 1.92
Waist Circumference (cm) 89.36 ± 8.37 89.14 ± 9.00 88.57 ± 8.78 88.64 ± 8.00
Hip Circumference (cm) 104.7 ± 6.7 104.1 ± 6.7 104.6 ± 6.4 104.3 ± 6.4
WHR 0.853 ± 0.017 0.855 ± 0.018 0.846 ± 0.016 0.849 ± 0.014
Systolic BP (mm Hg) 130.9 ± 11.7 130.0 ± 12.7 130.6 ± 11.1 129.1 ± 12.0
Diastolic BP (mm Hg) 82.0 ± 7.4 80.0 ± 5.9 81.7 ± 6.5 78.6 ± 4.4
Resting HR 63.43 ± 2.57 59.29 ± 1.91 * 62.14 ± 2.53 62.00 ± 2.73
IPAQ (METs/min) 1226 ± 336 1199 ± 281 922 ± 323 981 ± 336
* Significant difference from pre values at the same condition. BMI: Body Mass Index; WHR: Waist to Hip Ratio; BP:
Blood Pressure; HR: Heart Rate; IPAQ: International Physical Activity Questionnaire; METs: Metabolic Equivalent
of Task.
Table 2. Exercise performance parameters following α-lipoic acid supplementation (ALA) and
placebo (PL).
Parameter ALA PL
Pre Post Pre Post
Time to exhaustion (s) 198.9 ± 37.0 246.9 ± 37.6 207.9 ± 37.4 267.4 ± 36.4
MVC (Extensors)
Left 206.8 ± 18.1 205.3 ± 23.6 196.3 ± 18.8 202.8 ± 22.0
Right 213.8 ± 15.7 231.5 ± 22.5 209.8 ± 10.7 220.5 ± 11.1
MVC (Flexors)
Left 170.7 ± 14.4 169.3 ± 10.4 164.8 ± 10.9 172.7 ± 12.4
Right 169.2 ± 18.8 169.0 ± 13.8 167.7 ± 14.3 172.2 ± 14.2
MVC: Maximum Voluntary Contraction.
Regarding the indices of blood redox status, there was a significant increase in resting TAC
(Figure 1A) and a significant decrease in resting bilirubin (Figure 1C) concentrations following ALA.
Moreover, TAC increased immediately after and one hour after exercise following both ALA and PL
(Figure 1A), whereas bilirubin increased immediately after and one hour after exercise only following
ALA (Figure 1B). Moreover, there was a non-significant (p = 0.059) increase in bilirubin one hour after
exercise following PL (Figure 1C), and a non-significant (p = 0.06) increase in uric acid immediately
after exercise following ALA (Figure 1B). TBARS did not significantly change at any time point in both
conditions (Figure 2A).
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No significant change in uric acid both at rest and following exercise was found. Nevertheless,
a non-statistically significant (p = 0.06) increase immediately after exercise following ALA
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supplementation was observed. Previous data reported that ALA supplementation resulted in
significantly increased uric acid in individuals with G6PD deficiency but not in those with normal
enzyme activity [19]. Uric acid is main component of serum TAC [25]. However, a positive relationship
between uric acid and TAC that has been previously described [26] was not evident in the present study.
It is likely that uric acid levels were also affected by other factors than redox status. Another hypothesis
is that other TAC components than uric acid (i.e., bilirubin, vitamin C) may have contributed to
increased TAC levels.
Bilirubin increased significantly following ALA supplementation as a response to exercise
(immediately after and 1 h after). As already mentioned, bilirubin is a component of TAC, and
treatment with ALA supplementation influenced concomitant changes in these indices. In addition,
bilirubin is also an indicator of erythrocytes lysis. It is known that non-muscle damaging exercise
leads to short-lived haemolysis, which is most likely attributable to the break-up of erythrocytes due
to impact forces during exercise [27]. Theoretically, since G6PD deficient erythrocytes may be more
susceptible to oxidative stress, acute exercise could lead to haemolysis; however, no sign of haemolysis
was observed. This is in accordance with a previous study that used a similar exercise protocol [9].
Nonetheless, in another study where G6PD deficient participants performed high-intensity eccentric
exercise [11], marked and long-lived increases in bilirubin and haemoglobin were observed, indicating
haemolysis up to 4 days following exercise. It is noteworthy that the levels of these indices peaked
between 2 and 3 days, and not immediately after exercise. In the present study, blood samples were
obtained only immediately after and 1 h after exercise, and that does not allow us to draw safe
conclusions on whether the exercise protocol used cause haemolysis.
Resting levels of lipid peroxidation as examined by measuring TBARS concentration in serum
did not change at any treatment period. Previous studies have provided inconsistent results on
whether G6PD deficient individuals exhibit higher levels of lipid peroxidation than individuals
with normal G6PD activity [9,28,29]. Resting levels of protein oxidation as examined by measuring
protein carbonyl concentration also did not change at any treatment period. A previous study by
Theodorou et al. (2010) [11] showed that protein oxidation levels were similar in G6PD deficient
individuals and non-deficient ones. Taken together, G6PD deficient individuals may have developed
increased endogenous antioxidant defences in large tissues and do not exhibit higher levels of
oxidative stress compared to normal counterparts and ALA supplementation did not provide any
additional effect.
Moreover, TBARS and protein carbonyls did not change following acute exercise at any
treatment period. These results are not in accordance with the ones from a previous study that
has reported increased levels of these indices following acute exercise [9]. It could be hypothesized
that muscles of G6PD deficient individuals are not more susceptible to oxidative stress than those
of normal counterparts. However, these results could also be attributable to the exercise protocol.
Muscle-damaging exercise would provide more information.
5. Conclusions
In conclusion, ALA supplementation may contribute to enhanced antioxidant defence in
individuals with G6PD deficiency. Nonetheless, ALA supplementation does not change redox
responses to acute exercise and does not improve exercise performance. Muscle-damaging eccentric
exercise protocols and more time points of blood samples could provide more evidence.
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